An evidence-based, side-by-side comparison of two research compounds — mechanisms, studies, and clinical status.
Thymosin Beta-4 Fragment
Copper Tripeptide
| Property | TB-500 | GHK-Cu |
|---|---|---|
| Category | Thymosin Beta-4 Fragment | Copper Tripeptide |
| Formula | C212H350N56O78S | Gly-His-Lys·Cu²⁺ |
| Molecular Weight | 4,963.44 g/mol | 403.93 g/mol |
| Published Studies | 80+ | 60+ |
| Clinical Status | Preclinical Research | Active Research |
| Overview | A 43-amino-acid peptide studied for actin-binding protein interactions and cellular migration in wound healing models. | A naturally occurring copper-binding tripeptide studied for gene expression modulation across 4,000+ human genes. |
TB-500 is a synthetic version of Thymosin Beta-4, a 43-amino-acid peptide first isolated from the thymus gland. It plays a central role in actin polymerization.
TB-500 binds to G-actin monomers, regulating actin filament assembly critical for cell motility. The active region is LKKTETQ.
Not FDA-approved. Banned by WADA. Preclinical data only.
GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring tripeptide first isolated from human plasma by Dr. Loren Pickart in 1973. Its concentration in human plasma declines significantly with age — from ~200 ng/mL at age 20 to ~80 ng/mL by age 60.
A landmark 2012 study by Pickart et al. found that GHK-Cu influences the expression of 4,000+ human genes — roughly 6% of the human genome. The affected genes are involved in collagen synthesis, decorin production, antioxidant defense, and DNA repair pathways.
Educational content for informational purposes only. Not medical advice.